ibrutinib,rituximab
abbvie,janssen
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'mds']
ibrutinib.. will be the winner for sure if accessible keep in mind of secondary aml/mds with high dose chemotherapy #ash22 
Guidelines, updates, Questions, Meetings in Hematology.